Literature DB >> 7851021

The effect of free and liposome-encapsulated clodronate on the hepatic mononuclear phagocyte system in the rat.

J P Camilleri1, A S Williams, N Amos, A G Douglas-Jones, W G Love, B D Williams.   

Abstract

Clodronate, encapsulated within small unilamellar vesicles (SUVc) will deplete hepatic macrophages after intravenous injection. Functional studies, using probes to evaluate hepatic Fc and C3b uptake, showed a close correlation between the inhibition of receptor-mediated uptake and the depletion of hepatic macrophages. Twenty milligrams of clodronate encapsulated within SUVc produced > or = 90% inhibition of uptake and clearance of Fc- and C3b-coated erythrocytes and a comparable reduction of hepatic macrophage numbers. Inhibition of macrophage receptor-mediated uptake of these erythrocytes was closely related to the reduction in macrophage numbers. Repopulation of macrophages within the liver took place over 2 weeks. At 1 week after depletion, although repopulation was taking place, receptor-mediated function remained suppressed. In a preliminary experiment, treatment of rats with adjuvant arthritis with 20 mg clodronate encapsulated in SUV suppressed the inflammation and reversed the course of the disease, while treatment with 20 mg free clodronate in saline or 20 mg clodronate in multilamellar vesicles (MLVc) did not.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7851021      PMCID: PMC1534290          DOI: 10.1111/j.1365-2249.1995.tb05544.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  20 in total

1.  Specific accumulation of cholesterol-rich liposomes in the inflammatory tissue of rats with adjuvant arthritis.

Authors:  W G Love; N Amos; I W Kellaway; B D Williams
Journal:  Ann Rheum Dis       Date:  1990-08       Impact factor: 19.103

2.  Demonstration of hepatic Fc receptor function in vivo.

Authors:  N Yousaf; J C Howard; B D Williams
Journal:  Clin Exp Immunol       Date:  1989-11       Impact factor: 4.330

Review 3.  Monoclonal antibodies as tools to analyze the serological and genetic complexities of major transplantation antigens.

Authors:  J C Howard; G W Butcher; G Galfrè; C Milstein; C P Milstein
Journal:  Immunol Rev       Date:  1979       Impact factor: 12.988

4.  The alloantigenic organization of RT1Aa, a class I major histocompatibility complex molecule of the rat.

Authors:  A G Diamond; A P Larkins; B Wright; S T Ellis; G W Butcher; J C Howard
Journal:  Eur J Immunol       Date:  1984-05       Impact factor: 5.532

5.  Enhanced bacterial phagocytosis by peripheral blood monocytes in rheumatoid arthritis.

Authors:  M M Steven; S E Lennie; R D Sturrock; C G Gemmell
Journal:  Ann Rheum Dis       Date:  1984-06       Impact factor: 19.103

6.  Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis.

Authors:  C Q Chu; M Field; M Feldmann; R N Maini
Journal:  Arthritis Rheum       Date:  1991-09

7.  Efficient clodronate entrapment within multilamellar and unilamellar liposomes.

Authors:  W G Love; J P Camilleri; B D Williams
Journal:  J Pharmacol Toxicol Methods       Date:  1992-05       Impact factor: 1.950

8.  Comparative antiinflammatory and bone protective effects of two diphosphonates in adjuvant arthritis.

Authors:  L Flora
Journal:  Arthritis Rheum       Date:  1979-04

9.  Demonstration of novel anti-arthritic and anti-inflammatory effects of diphosphonates.

Authors:  C J Dunn; L A Galinet; H Wu; R A Nugent; S T Schlachter; N D Staite; D G Aspar; G A Elliott; N A Essani; N A Rohloff
Journal:  J Pharmacol Exp Ther       Date:  1993-09       Impact factor: 4.030

10.  Reversible depletion of synovial lining cells after intra-articular treatment with liposome-encapsulated dichloromethylene diphosphonate.

Authors:  P L van Lent; L van den Bersselaar; A E van den Hoek; M van de Ende; C D Dijkstra; N van Rooijen; L B van de Putte; W B van den Berg
Journal:  Rheumatol Int       Date:  1993       Impact factor: 2.631

View more
  8 in total

Review 1.  Targeted drug-delivery approaches by nanoparticulate carriers in the therapy of inflammatory diseases.

Authors:  Wiebke Ulbrich; Alf Lamprecht
Journal:  J R Soc Interface       Date:  2009-11-25       Impact factor: 4.118

2.  Differential effects of methotrexate and liposomally conjugated methotrexate in rat adjuvant-induced arthritis.

Authors:  A S Williams; J P Camilleri; N Amos; B D Williams
Journal:  Clin Exp Immunol       Date:  1995-12       Impact factor: 4.330

3.  Liposomal targeting of glucocorticoids to synovial lining cells strongly increases therapeutic benefit in collagen type II arthritis.

Authors:  J M Metselaar; W B van den Berg; A E M Holthuysen; M H M Wauben; G Storm; P L E M van Lent
Journal:  Ann Rheum Dis       Date:  2004-04       Impact factor: 19.103

4.  Methods for assessing splenic macrophage depletion by liposome encapsulated clodronate.

Authors:  J P Camilleri; A S Williams; N Amos; A G Douglas-Jones; W G Love; B D Williams
Journal:  Inflamm Res       Date:  1995-04       Impact factor: 4.575

5.  Zoledronate alters natural progression of tissue-engineered vascular grafts.

Authors:  Yu-Chun Chang; Junlang Li; Gabriel Mirhaidari; Jacob Zbinden; Jenny Barker; Kevin Blum; James Reinhardt; Cameron Best; John Kelly; Toshihiro Shoji; Tai Yi; Christopher Breuer
Journal:  FASEB J       Date:  2021-10       Impact factor: 5.834

Review 6.  Drugs in development: bisphosphonates and metalloproteinase inhibitors.

Authors:  Jon B Catterall; Tim E Cawston
Journal:  Arthritis Res Ther       Date:  2002-11-08       Impact factor: 5.156

7.  The Role of Microparticles in Rheumatic Diseases and their Potentials as Therapeutic Tools.

Authors:  Wen-Hai Shao
Journal:  J Mol Immunol       Date:  2016-07-19

8.  Nanoparticle clearance is governed by Th1/Th2 immunity and strain background.

Authors:  Stephen W Jones; Reid A Roberts; Gregory R Robbins; Jillian L Perry; Marc P Kai; Kai Chen; Tao Bo; Mary E Napier; Jenny P Y Ting; Joseph M Desimone; James E Bear
Journal:  J Clin Invest       Date:  2013-06-17       Impact factor: 14.808

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.